At that point I was on the board of directors of Glaxo, GlaxoSmithKline, and I tried out this idea on some of my colleagues within Glaxo and they said, oh, never work, would never be medicinal. Don't waste our time. Don't waste your time. I said, well, what's the data? There was no data. So, Steve [Benkovic] worked with his postdoc, another Steve, Steve Baker, and they made a whole series of small molecules with boron in a ring at an active site. And then they sent them to me and I tested them on a whole variety of pathogens, including yeast and of course HeLa cells because you want it to work in humans and lots of bacterial pathogens, including Brucella and lots of others. We had incredible activity. And we said, oh my God. I said, but we've got to do the critical experiment, make the same molecules, but put carbon back in instead of boron what would happen. We lost all activity. So, then Steve and I pooled our resources. We patented everything through Stanford and Penn State, and we bought the exclusive license.

Lucy Shapiro (b. 1940, New York City) is a developmental biologist and Professor Emeritus of Developmental Biology at Stanford University where she has been a faculty member since 1989. She held the Virginia and D.K. Ludwig Chair in Cancer Research and served as director of the Beckman Center for Molecular and Genetic Medicine. Dr. Shapiro’s lab has focused on studying Caulobacter crescentus, one of the simplest organisms that divides asymmetrically into different cell types, to uncover fundamental principles of developmental biology.

Dr. Shapiro received her Bachelor of Arts in Biology and Fine Arts from Brooklyn College in 1962, and her Ph.D. In Molecular Biology from Albert Einstein College of Medicine in 1966. In 1986, Shapiro moved to the Columbia University School of Medicine as the first female chair of the Department of Microbiology and Immunology. Two years later, in 1989, Shapiro moved to Stanford University and founded the Department of Developmental Biology.

In the early 1990s, Dr. Shapiro became involved in policy work. She was invited to the White House to speak to President Bill Clinton and his Cabinet about the potential threats to the public posed by the increase in antibiotic resistance, emerging infectious diseases, and the possibility of bioterrorism. She then went on to serve as a scientific advisor to the Clinton administration and advisor on bioterrorism to the secretary of homeland security, Tom Ridge, and to the secretary of state, Condoleezza Rice during the George W. Bush administration.

In addition to her research, Dr. Shapiro co-founded the anti-infectives discovery company Anacor Pharmaceuticals to develop new types of antibiotics and antifungals. This has resulted in the production of two FDA approved drugs; Kerydin, a treatment for toenail fungus and Crisaborole, to treat atopic dermatitis. Anacor Pharmaceuticals was acquired by Pfizer in May 2016. She also co-founded Boragen, an agricultural innovation company that merged with AgriMetis to form 5Metis, Inc, where she serves on the board. She also serves on the board of directors at GlaxoSmithKline and Pacific BioSciences, Inc.

Dr. Shapiro has received numerous awards including the National Medal of Science awarded by President Barack Obama, the Linus Pauling Medal, Dickson Prize in Science, Canada Gairdner International Award, Federation of American Societies for Experimental Biology (FASEB) Excellence in Science Award, the Selman Waksman Award, the Louisa Gross Horwitz Prize, the Abbott Lifetime Achievement Award, the John Scott Award, and the Pearl Meister Greengard Prize.